Alert detail
Proposed LCD DL40144: MolDX: Biomarker Testing for Risk Stratification in DCIS — Noridian
Policy ID: LCD-DL40144Specialty: OncologyAdded: 6/5/2026lcd
What changed
Impact of new MolDX LCD on DCIS biomarker testing billing.
Who’s affected: Oncology billing teams
Primary source: View the official CMS/MAC document ↗
Get the action steps and full analysis
This change affects 10 billing codes.
The full analysis, the revision comparison and the as-of-date version of this policy are what a partner packet carries. The source document above is free and always will be.